GLP ‐1 Receptor Agonists and Acne: Evidence and Inference
International Journal of Dermatology · 2026-08 · 65 (8) · 1766-1768
DOI: 10.1111/ijd.70368 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 07.03.2026. Verfasst von Marco Rocha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of São Paulo, São Paulo, Brazil. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
, The rapid expansion of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) from antidiabetic agents to cornerstone therapies for chronic weight management has substantially altered contemporary metabolic care. In parallel, dermatologists increasingly encounter patients receiving GLP-1 RAs who report new-onset or worsening acne, despite acne vulgaris not being consistently reported as an adverse event in pivotal randomized clinical trials [1, 2]. This apparent discrepancy between controlled trial data and real-world clinical impressions warrants careful interpretation grounded in available evidence. From an evidence-based perspective, the association between GLP-1 RAs and acne vulgaris appears weak. Meta-analyses and systematic reviews have not identified acne as a drug-specific adverse effect of GLP-1 RA therapy. The largest meta-analysis to date, which included 45 PubMed-indexed studies across multiple GLP-1 RA formulations, found no conclusive evidence that acne incidence was increased in treated patients [3]. Importantly, acne was neither a predefined outcome nor consistently reported in randomized trials, which argues against a robust causal relationship. Broader dermatologic reviews of GLP-1 RAs have described injection-site reactions and immune-mediated derma-toses but have not identified acne as a recurring or characteristic signal [1, 2]. In contrast, emerging real-world data suggest a more nuanced picture. A large retrospective cohort study reported higher
Autor:innen und Institutionen
- Federal University of São Paulo, São Paulo, Brazil.
- Centre Médical Laser Palaiseau, Private Practice, Palaiseau, France.
ORCID-Profile: Diala Haykal, Edileia Bagatin
Zitieren
APA
Rocha, M., Haykal, D., & Bagatin, E. (2026). GLP ‐1 Receptor Agonists and Acne: Evidence and Inference. International Journal of Dermatology, 65(8), 1766-1768. https://doi.org/10.1111/ijd.70368
Vancouver
Rocha M, Haykal D, Bagatin E. GLP ‐1 Receptor Agonists and Acne: Evidence and Inference. International Journal of Dermatology. 2026;65(8):1766-1768. doi:10.1111/ijd.70368
BibTeX
@article{Rocha2026,
author = {Rocha, Marco and Haykal, Diala and Bagatin, Edileia},
title = {GLP ‐1 Receptor Agonists and Acne: Evidence and Inference},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {8},
pages = {1766--1768},
doi = {10.1111/ijd.70368}
}
EUVIMED